Evidence map›Paper›PMID 19037996›Full record

ReviewCancer science2009

Spa-1 (Sipa1) and Rap signaling in leukemia and cancer metastasis.

Nagahiro Minato, Masakazu Hattori

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A scan for genes associated with cancer mortality and longevity in pedigree dog breeds.Mammalian genome : official journal of the International Mammalian Genome Society · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Blood advances · 2018
    Article
  12. Article
  13. Rap2B GTPase: structure, functions, and regulation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nagahiro MinatoDepartment of Immunology and Cell Biology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. minato@imm.med.kyoto-u.ac.jp
Masakazu Hattori
Kyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although Rap GTPases of the Ras family remained enigmatic for years, extensive studies in this decade have revealed diverse functions of Rap in the control of cell proliferation, differentiation, survival, adhesion, and movement. With the use of genetic engineering strategies, we have uncovered essential roles of Rap signaling in normal lymphohematopoietic cell development as well as its crucial involvement in the development of a wide spectrum of leukemia in manners highly dependent on the contexts of cell lineages. Incidentally, recent results also indicate an important role of Spa-1, a Rap GTPase-activating protein, in invasion and metastasis in human cancers. While it is unlikely that Rap can function as a classic oncogene by itself, like Ras, emerging findings unveil crucial involvements of Rap GTPases in the distinct aspects of malignancy, including leukemia genesis and cancer metastasis.

Indexed as

Neoplasm MetastasisAnimalsCell LineageGTPase-Activating ProteinsHumansLeukemiaLymphocytesMiceNuclear Proteinsrap GTP-Binding ProteinsSignal TransductionGTPase-Activating ProteinsNuclear Proteinsrap GTP-Binding ProteinsSIPA1 protein, human

Identifiers

PMID19037996
PMCPMC11158263
OpenAlexW2000520321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.